Fetal and neonatal effects of in utero exposure to perfluoroalkyl ether acids
Legacy, straight-chain perfluoroalkyl substances (PFAS), including PFOA and PFOS, have been removed from commerce due to widespread environmental contamination, long environmental and biological half-lives, nearly ubiquitous exposure to humans and wildlife, and various adverse effects associated with exposure. Perfluoroalkyl ether carboxylic acids, such as GenX, and perfluoroalkyl ether sulfonic acids, such as Nafion byproduct 2, are subclasses of PFAS that have recently been used as replacements for PFOA and PFOS. However, GenX and Nafion byproduct 2, among many other replacement PFAS, have little or no published toxicity studies for comparison to the legacy PFAS. Further, despite human biomonitoring data indicating widespread exposure to multiple PFAS, there is little to no in vivo toxicity data regarding mixture-based effects to inform cumulative risk assessment. This seminar will cover recent data generated from laboratory rat studies on the adverse maternal, fetal, and neonatal effects of in utero exposure to emerging PFAS compounds individually and as a mixture.